Sinovac Biotech (SVA)
(Delayed Data from NSDQ)
$8.47 USD
0.00 (0.00%)
Updated Dec 31, 1969 06:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
SVA 8.47 0.00(0.00%)
Will SVA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for SVA
SINOVAC Reports Unaudited First Half of 2024 Financial Results
Sinovac Biotech Experiences 2024 Mid-Year Downturn
Sernova to Present Promising Diabetes Treatment Data
Sernova Corp Appoints Jonathan Rigby as New CEO
Sernova Corp. Announces Appointment of New Chief Executive Officer